JPH08502485A - 緑内症(glaucoma)治療のための、プロスタグランジンとクロニジン誘導体の組合わせ - Google Patents
緑内症(glaucoma)治療のための、プロスタグランジンとクロニジン誘導体の組合わせInfo
- Publication number
- JPH08502485A JPH08502485A JP6510215A JP51021594A JPH08502485A JP H08502485 A JPH08502485 A JP H08502485A JP 6510215 A JP6510215 A JP 6510215A JP 51021594 A JP51021594 A JP 51021594A JP H08502485 A JPH08502485 A JP H08502485A
- Authority
- JP
- Japan
- Prior art keywords
- mixture
- pgf
- alpha
- pge
- deoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.緑内症の治療のための局所眼科用混合物(topical ophthalmic composition) であって、 薬学的に効果的(pharmaceutically effectvie)な量のプロスタグランジンと薬学 的に効果的な量のクロニジン誘導体との組合わせを有する混合物。 2.請求の範囲1に記載の混合物であって、該クロニジン誘導体が、 a)化学式 (ここで:R1とR2の一つは水素であって、R1とR2はH,OH,NHR’、お よびO−CO−CH2−R’から選ばれ、R’はH,C1−C4アルキルから選ば れ;および、XおよびYはBr,Cl,CH3,およびCH2CH3から選ばれる 。) である化合物と、 b)化学式 (ここで:少なくともXおよびYの一つはアルキルであって、XおよびYはBr ,Cl,CH3,およびCH2CH3から選ばれる。) である化合物とからなる群から選ばれる混合物。 3.請求の範囲1に記載の混合物であって、 該クロニジン誘導体の最終的な成分濃度が約0.02と約2.0重量%の間であ り、かつ、該プロスタグランジンの最終的な成分濃度が約0.00001と約0 .2重量%の間である混合物。 4.請求の範囲3に記載の混合物であって、 該クロニジン誘導体の最終的な成分濃度が約0.05と約1.0重量%の間であ る混合物。 5.請求の範囲4に記載の混合物であって、 該クロニジン誘導体の最終的な成分濃度が約0.1と約0.25重量%の間であ る混合物。 6.請求の範囲3に記載の混合物であって、 該プロスタグランジンの最終的な成分濃度が約0.0001と約0.01重量% の間である混合物。 7.請求の範囲1に記載の混合物であって、 該プロスタグランジンが、 PGF2α,PGE2、PGE1、プロスタサイクリン、15(S)−メチル−P GF2α、16、16−ジメチル−PGF2α、15(S)−メチル−PGE2、 16、16−ジメチル−PGE2、17、18、19、20−テトラノル−16 −フェノキシ−PGE2、17、18、19、20−テトラノル−16−フェノ キシ−PGF2α、18、19、20−トリノル−17−フェニル−PGE2、1 8、19、20−トリノル−17−フェニル−PGF2α、トリモプロスチル(t rimoprostil)、RS−84−135、リオプロスチル、S−1033(15− デスヒドロキシPGF2α、ナトリウム塩)、S−747260、ノクロプロス ト、CSー412、YPG−209、K−10134、クロプロステノール、フ ルプロステノール、ルプロスチオール、エチプロストロン、チアプロスト、SQ 27986、ZK138519、13、14−ジヒドロZK138519、ZK 118182、13、14−ジヒドロZK118182、ZK110841、1 3、14−ジヒドロZ KII0841、PhZA41(ラタノプロスト)、R O−221327、HR−446、HR−601、ONO−1206、UFO− 21、11−デオキシ−PGE2、11−デオキシ−PGF2α、11−デオキ シ−16、16−ジメ チルPGE2、11−デオキシ−15(S)−メチル−PEG2、11−デオキ シ−15(S)−メチル−PGF2α、ミソプロストール、エニソプロスト、M DL−646、CL−115、574、CL−115、347、TR−4161 、TR−4752、TR−4367、CP−27987、スルプロストン、ゲメ プロスト、アルフアプロストール、デルプロステナ一ト、プロスタレン、フェン プロスタレン、CL−116、069、ONO−995、RO−229648で あり、およびそれらの薬学上許容されるエステルおよび塩からなる群から選ばれ る混合物。 8.請求の範囲7に記載の混合物であって、 該プロスタグランジンが、 PGF2α−1−イソプロピルエステル、PGF2α−1−エチルエステル、RO ー229648、SQ27986、ZK138519、13,14−ジヒドロZ K138519、ZK110841、13,14−ジヒドロZK120841、 PhXA41、および19,8,19,20−トリノル−17−フェニル−PG F2α−1−メチルエステルからなる群から選ばれる混合物。 9.請求の範囲1−8のいずれかに記載の混合物であって、 さらに陰イオン性、ムコ様ポリマーおよび細分化薬物運搬物質を含む混合物。 10.請求の範囲1−8のいずれかに記載の混合物であって、 さらにゲル状ポリサッカライドおよび細分化薬物運搬物質を含む混合物。 11.請求の範囲1−10のいずれかに記載の混合物の緑内症治療への使用方法 。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US96006592A | 1992-10-13 | 1992-10-13 | |
US960,065 | 1992-10-13 | ||
US07/960,065 | 1992-10-13 | ||
PCT/US1993/009742 WO1994008585A1 (en) | 1992-10-13 | 1993-10-12 | Combinations of prostaglandins and clonidine derivatives for the treatment of glaucoma |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH08502485A true JPH08502485A (ja) | 1996-03-19 |
JP3002258B2 JP3002258B2 (ja) | 2000-01-24 |
Family
ID=25502747
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP6510215A Expired - Fee Related JP3002258B2 (ja) | 1992-10-13 | 1993-10-12 | 緑内障(glaucoma)治療のための、プロスタグランジンとクロニジン誘導体の組合わせ |
Country Status (10)
Country | Link |
---|---|
US (3) | US5480900A (ja) |
EP (1) | EP0664707B1 (ja) |
JP (1) | JP3002258B2 (ja) |
AT (1) | ATE153855T1 (ja) |
AU (1) | AU674038B2 (ja) |
CA (1) | CA2146127C (ja) |
DE (1) | DE69311361T2 (ja) |
ES (1) | ES2105333T3 (ja) |
HK (1) | HK1007102A1 (ja) |
WO (1) | WO1994008585A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004530687A (ja) * | 2001-05-17 | 2004-10-07 | アラーガン、インコーポレイテッド | 眼内圧降下剤としてのプロスタン酸誘導体 |
KR101118935B1 (ko) * | 2003-08-21 | 2012-03-13 | 가부시키가이샤 아루떼꾸 우에노 | 안과용 조성물 |
JP2014522844A (ja) * | 2011-06-29 | 2014-09-08 | ザ ペン ステート リサーチ ファウンデーション | 白血病を治療するための組成物、方法及びキット |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6184250B1 (en) | 1993-08-03 | 2001-02-06 | Alcon Laboratories, Inc. | Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension |
US5510383A (en) * | 1993-08-03 | 1996-04-23 | Alcon Laboratories, Inc. | Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension |
DE4330177A1 (de) * | 1993-08-31 | 1995-03-02 | Schering Ag | Neue 9-Chlor-prostaglandin-derivate |
US6294563B1 (en) | 1994-10-27 | 2001-09-25 | Allergan Sales, Inc. | Combinations of prostaglandins and brimonidine or derivatives thereof |
WO1996013267A2 (en) * | 1994-10-27 | 1996-05-09 | Allergan | Combinations of prostaglandins and brimonidine or derivatives thereof for the treatment of glaucoma |
US5631287A (en) * | 1994-12-22 | 1997-05-20 | Alcon Laboratories, Inc. | Storage-stable prostaglandin compositions |
AU5258698A (en) | 1996-11-12 | 1998-06-03 | Alcon Laboratories, Inc. | 15-ketal prostaglandins for the treatment of glaucoma or ocular hypertension |
WO1998039293A2 (en) * | 1997-03-07 | 1998-09-11 | Alcon Laboratories, Inc. | 13-thia prostaglandins for use in glaucoma therapy |
SE9702706D0 (sv) * | 1997-07-11 | 1997-07-11 | Pharmacia & Upjohn Ab | Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma |
JP2002521333A (ja) * | 1998-07-21 | 2002-07-16 | メルク エンド カムパニー インコーポレーテッド | 高眼圧治療用眼薬組成物 |
US6417228B1 (en) | 1998-11-02 | 2002-07-09 | Alcon Manufacturing, Ltd.. | 13-Aza prostaglandins for the treatment of glaucoma and ocular hypertension |
US6160013A (en) * | 1998-12-17 | 2000-12-12 | Alcon Laboratories, Inc. | 14-aza prostaglandins for the treatment of glaucoma and ocular hypertension |
US6211226B1 (en) | 1998-12-17 | 2001-04-03 | Alcon Laboratories, Inc. | 11-Aza prostaglandins for the treatment of glaucoma and ocular hypertension |
US6545045B1 (en) | 1998-12-24 | 2003-04-08 | Alcon Manufacturing, Ltd. | Prostaglandin E agonists for treatment of glaucoma |
CA2364944C (en) * | 1999-03-05 | 2009-01-20 | The Procter & Gamble Company | C16 unsaturated fp-selective prostaglandins analogs |
ES2232434T3 (es) | 1999-03-05 | 2005-06-01 | Duke University | Analogos de prostaglandinas c-16 fp selectivas insaturadas. |
US20020037914A1 (en) * | 2000-03-31 | 2002-03-28 | Delong Mitchell Anthony | Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins |
US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
US20020172693A1 (en) * | 2000-03-31 | 2002-11-21 | Delong Michell Anthony | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
US20020146439A1 (en) * | 2000-03-31 | 2002-10-10 | Delong Mitchell Anthony | Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins |
US20020198210A1 (en) * | 2001-05-03 | 2002-12-26 | Allergan Sales Inc. | Alpha-2-adrenergic agonist/fatty acid compositions |
US20020198209A1 (en) | 2001-05-03 | 2002-12-26 | Allergan Sales Inc. | Compositions having enhanced pharmacokinetic characteristics |
AU2002256471B2 (en) * | 2001-05-03 | 2007-05-24 | Allergan, Inc. | Compositions having enhanced pharmacokinetic characteristics |
US7351404B2 (en) | 2002-02-04 | 2008-04-01 | Allergan, Inc. | Method of enhancing hair growth |
US8758733B2 (en) | 2002-02-04 | 2014-06-24 | Allergan, Inc. | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
US9216183B2 (en) | 2002-02-04 | 2015-12-22 | Allergan, Inc. | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
US8580851B2 (en) | 2002-08-21 | 2013-11-12 | Sucampo Ag | Ophthalmic solution |
EP1704141B1 (en) * | 2004-01-05 | 2016-02-24 | Nicox S.A. | Prostaglandin nitrooxyderivatives |
CA2613748A1 (en) * | 2005-06-29 | 2007-01-04 | Pfizer Inc. | Prostaglandin derivatives |
US8722739B2 (en) | 2008-10-29 | 2014-05-13 | Novaer Holdings, Inc. | Amino acid salts of prostaglandins |
US8623918B2 (en) * | 2008-10-29 | 2014-01-07 | Novaer Holdings, Inc. | Amino acid salts of prostaglandins |
US20100204335A1 (en) * | 2008-12-01 | 2010-08-12 | Allergan, Inc. | Kit and composition for eyelash growth |
WO2010116270A1 (en) | 2009-04-10 | 2010-10-14 | Pfizer Inc. | Ep2/4 agonists |
US9149484B2 (en) | 2009-11-09 | 2015-10-06 | Allergan, Inc. | Compositions and methods for stimulating hair growth |
JP5982287B2 (ja) * | 2009-11-09 | 2016-08-31 | アラーガン、インコーポレイテッドAllergan,Incorporated | 発毛を刺激する組成物および方法 |
US8859616B2 (en) | 2011-01-21 | 2014-10-14 | Allergan, Inc. | Compounds and methods for enhancing hair growth |
CN103889401B (zh) | 2011-08-29 | 2017-10-13 | Qlt公司 | 持续释放递送活性剂以治疗青光眼和高眼压 |
CA2872338C (en) | 2012-05-03 | 2021-09-14 | Qlt Inc. | Drug delivery system and methods of treating open angle glaucoma and ocular hypertension |
JP2018510668A (ja) | 2015-01-12 | 2018-04-19 | ケダリオン セラピューティックス,インコーポレイテッド | 微小液滴の繰り出し装置及び方法 |
US9827225B2 (en) * | 2016-01-25 | 2017-11-28 | Jenivision Inc. | Use of prostacyclin antagonists for treating ocular surface nociception |
BR112019009330A2 (pt) | 2016-11-08 | 2019-07-30 | Bausch & Lomb | composto |
US11679028B2 (en) | 2019-03-06 | 2023-06-20 | Novartis Ag | Multi-dose ocular fluid delivery system |
CA3180199A1 (en) | 2020-04-17 | 2021-10-21 | Yehuda Ivri | Hydrodynamically actuated preservative free dispensing system |
US11938057B2 (en) | 2020-04-17 | 2024-03-26 | Bausch + Lomb Ireland Limited | Hydrodynamically actuated preservative free dispensing system |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3190802A (en) * | 1961-10-09 | 1965-06-22 | Boehringer Sohn Ingelheim | Shaving composition and method of using same |
DE1670274A1 (de) * | 1966-10-31 | 1970-07-16 | Boehringer Sohn Ingelheim | Neues Verfahren zur Herstellung von 2-Arylamino-1,3-diazacycloalkenen-(2) |
US3755426A (en) * | 1971-07-02 | 1973-08-28 | American Home Prod | 10-haloprostaglandin-a derivatives |
CA1045131A (en) * | 1972-07-24 | 1978-12-26 | Middleton B. Floyd (Jr.) | Derivatives of 9-hydroxy-13-trans-prostenoic acid |
US3873607A (en) * | 1972-07-24 | 1975-03-25 | American Cyanamid Co | 3-Oxa(and thia) 11-deoxy PGE |
US4110368A (en) * | 1972-07-24 | 1978-08-29 | American Cyanamid Company | Hydro substituted prostanoic acids and esters |
US3884969A (en) * | 1973-04-20 | 1975-05-20 | American Cyanamid Co | Novel prostaglandins |
US4029681A (en) * | 1976-02-13 | 1977-06-14 | The Upjohn Company | 13,14-Didehydro-PG analogs |
US4321405A (en) * | 1976-03-03 | 1982-03-23 | American Cyanamid Company | 15,16-Dioxy prostenoic acids and esters |
US4097489A (en) * | 1977-06-17 | 1978-06-27 | The Upjohn Company | 9-Deoxy-9α,6-nitrilo or 6,9α-imino-PGF compounds |
US4343949A (en) * | 1977-09-22 | 1982-08-10 | American Cyanamid Company | Novel 2-substituted-3,4-epoxycyclopentan-1-ones, 2-substituted-3,4-epoxycyclopentan-1-ols, and various 2-substituted-cyclopentenones |
US4288616A (en) * | 1979-04-02 | 1981-09-08 | The Upjohn Company | 13,14-Didehydro-11-deoxy-11-hydroxymethyl-19-oxo-PGF2 compounds |
US4291175A (en) * | 1980-04-03 | 1981-09-22 | American Cyanamid Company | 1-Hydroxymethyl-11-deoxy-15-hydroxy-prosten-1-ol-derivatives |
NZ200429A (en) * | 1981-04-30 | 1984-10-19 | Smith & Nephew Ass | Applicator for placing pharmaceutically active agent in contact with moist surface,e.g.,eye |
US4730013A (en) * | 1981-10-08 | 1988-03-08 | Merck & Co., Inc. | Biosoluble ocular insert |
US4461904A (en) * | 1981-11-20 | 1984-07-24 | Alcon Laboratories, Inc. | 2-(Trisubstituted phenylimino)-imidazolines |
US4517199A (en) * | 1981-11-20 | 1985-05-14 | Alcon Laboratories, Inc. | Method for lowering intraocular pressure using phenylimino-imidazoles |
US4515800A (en) * | 1981-11-20 | 1985-05-07 | Icilio Cavero | Method of lowering intraocular pressure using phenylimino-imidazoles |
US4599353A (en) * | 1982-05-03 | 1986-07-08 | The Trustees Of Columbia University In The City Of New York | Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma |
US4614825A (en) * | 1982-05-17 | 1986-09-30 | E. R. Squibb & Sons, Inc. | 7-oxabicycloheptane and 7-oxabicycloheptene compounds |
US4576962A (en) * | 1983-10-19 | 1986-03-18 | The Procter & Gamble Company | Prostaglandin analogues |
DE3347128A1 (de) * | 1983-12-22 | 1985-07-11 | Schering AG, 1000 Berlin und 4709 Bergkamen | 9-halogen-(delta)(pfeil hoch)2(pfeil hoch)-prostaglandinderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
US4911920A (en) * | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
US4587257A (en) * | 1984-12-14 | 1986-05-06 | Alcon Laboratories, Inc. | Control of ocular bleeding using clonidine derivatives |
ATE76750T1 (de) * | 1987-04-03 | 1992-06-15 | Univ Columbia | Anwendung eines prostaglandins in mischung mit einem adrenergischen blocker zur verminderung des augen-innendruckes. |
CA1324129C (en) * | 1987-04-30 | 1993-11-09 | Ryuzo Ueno | Prostaglandins of the f series |
CA1322197C (en) * | 1987-07-17 | 1993-09-14 | Bernd Buchmann | 9-halogen-(z) prostaglandin derivatives, process for their production and their use as pharmaceutical agents |
WO1990002553A1 (en) * | 1988-09-06 | 1990-03-22 | Pharmacia Ab | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
DE68928551T2 (de) * | 1988-10-01 | 1998-04-23 | R Tech Ueno Ltd | Oculare hypotensive Mittel |
CA2014038A1 (en) * | 1989-05-25 | 1990-11-25 | Charles Gluchowski | Intraocular pressure reducing 15-acyl prostaglandins |
DE3923797A1 (de) * | 1989-07-14 | 1991-01-24 | Schering Ag | 9-fluor-prostaglandin-derivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung |
US4994274A (en) * | 1989-07-27 | 1991-02-19 | Allergan, Inc. | Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using |
US5093329A (en) * | 1990-03-12 | 1992-03-03 | Allergan, Inc. | Intraocular pressure reducing prostaglandin-like 7-oxabicyclo derivatives |
EP0521009A4 (en) * | 1990-03-19 | 1993-02-24 | Allergan, Inc. | Use of 5-trans prostaglandin f 2-g(a)? as an ocular hypotensive agent |
CA2042934C (en) * | 1990-05-22 | 2002-04-23 | Ryuji Ueno | Treatment of ocular hypertension with an ocular synergistic combination |
US5212162A (en) * | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
-
1993
- 1993-10-12 WO PCT/US1993/009742 patent/WO1994008585A1/en active IP Right Grant
- 1993-10-12 DE DE69311361T patent/DE69311361T2/de not_active Expired - Lifetime
- 1993-10-12 JP JP6510215A patent/JP3002258B2/ja not_active Expired - Fee Related
- 1993-10-12 EP EP93923372A patent/EP0664707B1/en not_active Expired - Lifetime
- 1993-10-12 AU AU53286/94A patent/AU674038B2/en not_active Ceased
- 1993-10-12 CA CA002146127A patent/CA2146127C/en not_active Expired - Fee Related
- 1993-10-12 ES ES93923372T patent/ES2105333T3/es not_active Expired - Lifetime
- 1993-10-12 AT AT93923372T patent/ATE153855T1/de not_active IP Right Cessation
-
1995
- 1995-04-10 US US08/422,570 patent/US5480900A/en not_active Expired - Lifetime
- 1995-12-12 US US08/571,326 patent/US5605922A/en not_active Expired - Lifetime
-
1997
- 1997-02-21 US US08/803,667 patent/US5811443A/en not_active Expired - Fee Related
-
1998
- 1998-06-24 HK HK98106242A patent/HK1007102A1/xx not_active IP Right Cessation
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004530687A (ja) * | 2001-05-17 | 2004-10-07 | アラーガン、インコーポレイテッド | 眼内圧降下剤としてのプロスタン酸誘導体 |
KR101118935B1 (ko) * | 2003-08-21 | 2012-03-13 | 가부시키가이샤 아루떼꾸 우에노 | 안과용 조성물 |
JP2014522844A (ja) * | 2011-06-29 | 2014-09-08 | ザ ペン ステート リサーチ ファウンデーション | 白血病を治療するための組成物、方法及びキット |
Also Published As
Publication number | Publication date |
---|---|
DE69311361T2 (de) | 1998-01-08 |
AU5328694A (en) | 1994-05-09 |
JP3002258B2 (ja) | 2000-01-24 |
ES2105333T3 (es) | 1997-10-16 |
EP0664707A1 (en) | 1995-08-02 |
ATE153855T1 (de) | 1997-06-15 |
HK1007102A1 (en) | 1999-04-01 |
US5811443A (en) | 1998-09-22 |
WO1994008585A1 (en) | 1994-04-28 |
US5480900A (en) | 1996-01-02 |
US5605922A (en) | 1997-02-25 |
AU674038B2 (en) | 1996-12-05 |
DE69311361D1 (de) | 1997-07-10 |
CA2146127C (en) | 2000-06-13 |
EP0664707B1 (en) | 1997-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH08502485A (ja) | 緑内症(glaucoma)治療のための、プロスタグランジンとクロニジン誘導体の組合わせ | |
JP3719609B2 (ja) | 緑内障および眼虚血の治療のための特定のイソキノリンスルホニル化合物の使用 | |
US6294563B1 (en) | Combinations of prostaglandins and brimonidine or derivatives thereof | |
AU2008216497B2 (en) | Ophthalmic compositions containing a synergistic combination of three polymers | |
JPH10503470A (ja) | 減少した粘度を有する眼科治療用組成物 | |
JP2013525508A (ja) | 新規な点眼組成物 | |
WO1996013267A2 (en) | Combinations of prostaglandins and brimonidine or derivatives thereof for the treatment of glaucoma | |
EP0979652A1 (en) | Remedial composition for intraocular hypertension or glaucoma | |
US20130023575A1 (en) | Compositions and methods for the treatment of ocular surface allergies | |
KR20140035363A (ko) | 안정피로 치료 방법 | |
JP4300347B2 (ja) | ブナゾシンとプロスタグランジン類からなる緑内障治療剤 | |
CA2356912C (en) | Pharmaceutical compositions for the treatment of ocular hypertension or glaucoma | |
WO2003063879A1 (fr) | Remedes contre le glaucome contenant de la bunazosine et des prostaglandines | |
CA2240271C (en) | Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia | |
JP2004522711A (ja) | 眼内圧の低下および制御のための組み合わせ治療 | |
EP0521009A1 (en) | 5-trans-prostaglandin-2-alpha as an ocular hypotensive agent | |
TWI253345B (en) | Ophthalmic composition for the treatment of glaucoma, ocular hypertension, ocular ischemia and related disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081112 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091112 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091112 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101112 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111112 Year of fee payment: 12 |
|
LAPS | Cancellation because of no payment of annual fees |